Psychiatrictimes

Published September 30, 2026 · Updated October 1, 2026

Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression

Read the full story at Psychiatrictimes

Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.